The Campaign for Sustainable Rx Pricing (CSRxP) wishes to commend you for your strong bipartisan efforts to lower prescription drug prices for Americans by moving forward with the U.S. Senate Committee on Finance package on drug pricing. CSRxP believes that the Senate Finance package is a good first step in slowing the unsustainable growth…
07-24-2019As prescription drug prices continue to rise, many stakeholders have debated how to slow the trend and who should pay for it. The Medicare Advantage and Part D programs remain at the center of this discussion. Organizations such as the Medicare Payment Advisory Commission (“MedPAC”) and the American Action Form (“AAF”) as well as…
06-24-2019The Campaign for Sustainable Rx Pricing (CSRxP) is a broad-based coalition of leaders – physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists and businesses — promoting bipartisan, market-based solutions to lower drug prices in America. We appreciate the bipartisan attention and activity that lawmakers in Congress have placed on tackling the crisis of rising…
06-18-2019Drug prices are out of control. But Big Pharma is posting record profits. Where is all that money going? Not research and development. For the top ten U.S. companies, nearly 80% of every Big Pharma dollar goes to something other than R&D.¹
05-14-2019Despite efforts from the brand drug industry to suggest otherwise, brand pharmaceutical companies – and pharmaceutical companies alone – are the drivers of the high drug prices American consumers and taxpayers face every day. Brand manufacturers set unsustainably high launch prices for their products and typically increase those prices at rates that far exceed…
04-8-2019On behalf of the Campaign for Sustainable Rx Pricing (CSRxP), a nonpartisan coalition of doctors, physicians, nurses, hospitals, consumers, health plans, PBMs, pharmacists, patient advocates and businesses committed to lowering drug prices, congratulations on being elected to represent your constituents in the 116th Congress. Our organization believes no one should ever have to choose…
01-30-2019Drug prices in the United States are too high and continue to skyrocket. The unsustainable cost of prescription drugs not only puts pressure on the health care system but increasingly; patients, employers, and providers are paying prices that are too high.
01-6-2019The current market for pricing drugs in the United States is broken, and it’s unsustainable for American businesses, families, and our economy. Today, prescription drug expenditures make up nearly 20 percent of all health care costs, and prescription spending is growing faster than any other part of the health care dollar.
01-6-2019Drug prices in the United States are too high and sharply rising prescription drug prices threaten the affordability of health care and the vitality of our entire economy. CSRxP has developed market-based reforms that restore a functioning market by increasing transparency, promoting competition and innovation, and that result in value.
12-21-2018Dear Administrator Verma: The Campaign for Sustainable Rx Pricing (CSRxP) is a nonpartisan coalition of organizations committed to fostering an informed discussion on sustainable drug pricing and developing bipartisan, market-based solutions that promote competition, transparency, and value to improve affordability while maintaining patient access to innovative prescription drugs that can improve health outcomes and…
12-17-2018Dear Leader McConnell, Leader Schumer, Speaker Ryan and Leader Pelosi: We are writing to urge you to preserve the actions Congress took in the Bipartisan Budget Act of 2018 (BBA) to protect seniors and taxpayers from out-of-control drug prices as you embark on the lame duck session of Congress. Over the past five years,…
11-13-2018Dear Leader McConnell, Leader Schumer, Speaker Ryan and Leader Pelosi: We are writing to urge you to preserve the actions Congress took in the Bipartisan Budget Act (BBA) of 2018 to protect seniors and taxpayers from out-of-control drug prices. Over the past five years, drug manufacturers have increased the prices of brand name drugs…
09-25-2018Dear Chairman Frelinghuysen, Ranking Member Lowey, Chairman Cole, and Ranking Member DeLauro: The Campaign for Sustainable Rx Pricing (CSRxP) is writing to encourage you to maintain the Senate’s inclusion of a provision in the final Labor-HHS Appropriations bill to provide funding to enable the U.S. Department of Health and Human Services (HHS) to require…
08-27-2018Dear Commissioner Gottlieb: We appreciate the Food and Drug Administration’s (FDA) recent actions regarding biosimilars – specifically the FDA’s Biosimilars Action Plan. As you know, one of the most important ways the FDA can help increase marketplace competition is by finalizing its guidance, “Considerations in Demonstrating Interchangeability With a Reference Product” regarding the process…
08-23-2018Dear Secretary Azar: The Campaign for Sustainable Rx Pricing (CSRxP) is a nonpartisan coalition of organizations committed to fostering an informed discussion on sustainable drug pricing and to developing bipartisan, market-based solutions that promote competition, transparency, and value to improve affordability while maintaining patient access to innovative prescription drugs. Our members represent organizations including consumers…
07-13-2018Consumers currently spend 23 cents of every health care dollar on prescription drugs – an amount that can and must come down, as needlessly high drug prices and out-of-pocket spending threaten the financial security, health and well-being of American patients and their families, as well as strain Federal and State budgets.1 As such, CSRxP…
07-13-2018Testimony Submitted for the Record U.S. Senate Finance Committee Hearing: “Prescription Drug Affordability and Innovation: Addressing Challenges in Today’s Market” – Chairman Hatch, Ranking Member Wyden, and members of the Senate Finance Committee, the Campaign for Sustainable Rx Pricing (CSRxP) thanks you for the opportunity to submit testimony for the record on the critically…
06-26-2018Dear Chairman Grassley and Ranking Member Feinstein: We, the undersigned, commend you for your leadership and commitment to reducing out-of-control prescription drug prices and stopping anti-competitive abuses that keep drug prices high. We are encouraged that the Senate Judiciary Committee has noticed a markup of the Creating and Restoring Equal Access to Equivalent Samples…
06-7-2018